Cargando…

Impact of COVID‐19 versus chronic rhinosinusitis/rhinitis associated olfactory dysfunction on health utility and quality of life

BACKGROUND: Olfactory dysfunction (OD) is associated with both post‐viral and inflammatory etiologies such as COVID‐19 and chronic rhinosinusitis/rhinitis (CRS/R) respectively, to result in reduced quality of life (QoL). However, the former typically induces a sudden‐onset OD while the latter has a...

Descripción completa

Detalles Bibliográficos
Autores principales: Luong, Thanh, Jang, Sophie S., Said, Mena, DeConde, Adam S., Yan, Carol H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9538416/
https://www.ncbi.nlm.nih.gov/pubmed/36249088
http://dx.doi.org/10.1002/lio2.921
Descripción
Sumario:BACKGROUND: Olfactory dysfunction (OD) is associated with both post‐viral and inflammatory etiologies such as COVID‐19 and chronic rhinosinusitis/rhinitis (CRS/R) respectively, to result in reduced quality of life (QoL). However, the former typically induces a sudden‐onset OD while the latter has a gradual presentation. This study aims to establish and compare health utility values (HUVs) and olfactory‐specific QoL measurements between patients with COVID‐19 and CRS/R related OD. METHODS: This prospective study surveyed COVID‐19 and CRS/R patients with self‐reported OD using HUV assessments (EuroQol‐visual analog scale [EQ‐VAS], EuroQol‐5 dimension [EQ‐5D], time trade‐off [TTO]) and olfactory and sinonasal QoL measures (questionnaire of olfactory disorders –negative and positive statements [QOD‐NS + PS] and sino‐nasal outcome test [SNOT‐22]). A subgroup of subjects completed objective olfactory testing. Intergroup mean scores were compared using Mann–Whitney U tests. RESULTS: One hundred eleven subjects were enrolled: mean age ± SD (43.0 ± 15.4 years), 55.9% female. CRS/R was associated with lower HUVs as measured by EQ‐VAS (CRS/R: 0.67 ± 0.18 vs. COVID‐19: 0.74 ± 0.19, p = .03) and worse SNOT‐22 scores in both overall (CRS/R: 49.03 ± 21.04 vs. COVID‐19: 27.58 ± 18.45, p < .001) and subgroup analysis of objectively confirmed OD subjects (CRS/R: 52.40 ± 22.78 vs. COVID‐19: 29.84 ± 21.10, p = .01). On the other hand, COVID‐19 has greater burden on olfactory‐specific QoL (QOD‐NS + PS, COVID‐19: 23.19 ± 13.73 vs. CRS/R: 17.25 ± 11.38, p = .04). Both groups demonstrated a similar decrease in health using the EQ‐5D assessment. CONCLUSION: CRS/R associated OD has a more severe impact on general health and sinonasal specific QoL outcomes, while COVID‐19 associated OD has a greater burden on olfactory‐specific QoL. LEVEL OF EVIDENCE: Level 2c.